JPS6130567A - 尿素の安定化法 - Google Patents
尿素の安定化法Info
- Publication number
- JPS6130567A JPS6130567A JP15258284A JP15258284A JPS6130567A JP S6130567 A JPS6130567 A JP S6130567A JP 15258284 A JP15258284 A JP 15258284A JP 15258284 A JP15258284 A JP 15258284A JP S6130567 A JPS6130567 A JP S6130567A
- Authority
- JP
- Japan
- Prior art keywords
- urea
- amino acid
- basic amino
- aqueous solution
- acid salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 239000004202 carbamide Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 4
- 230000000087 stabilizing effect Effects 0.000 title claims description 3
- -1 amino acid salt Chemical class 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 abstract description 8
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 206010021198 ichthyosis Diseases 0.000 abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002934 diuretic Substances 0.000 abstract description 3
- 230000001882 diuretic effect Effects 0.000 abstract description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 abstract description 2
- 239000004475 Arginine Substances 0.000 abstract description 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004472 Lysine Substances 0.000 abstract description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract description 2
- 206010048218 Xeroderma Diseases 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 2
- 239000002537 cosmetic Substances 0.000 abstract description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 229960003104 ornithine Drugs 0.000 abstract description 2
- 229940071139 pyrrolidone carboxylate Drugs 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 abstract description 2
- 102000011782 Keratins Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000009413 insulation Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003244 ornithine hydrochloride Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15258284A JPS6130567A (ja) | 1984-07-23 | 1984-07-23 | 尿素の安定化法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15258284A JPS6130567A (ja) | 1984-07-23 | 1984-07-23 | 尿素の安定化法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6130567A true JPS6130567A (ja) | 1986-02-12 |
| JPH0531540B2 JPH0531540B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-05-12 |
Family
ID=15543613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15258284A Granted JPS6130567A (ja) | 1984-07-23 | 1984-07-23 | 尿素の安定化法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6130567A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067701U (ja) * | 1992-07-02 | 1994-02-01 | 旭光学工業株式会社 | 内視鏡の送気装置 |
| WO1997005862A3 (en) * | 1995-08-03 | 1997-04-17 | Sigma Tau Ind Farmaceuti | Use of basic amino acids and derivatives for lowering ceramide levels |
| JP2006524199A (ja) * | 2003-04-24 | 2006-10-26 | ロレアル | 美容的ピーリング方法 |
| US8440172B2 (en) | 2007-07-09 | 2013-05-14 | Symrise Ag | Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0 |
| JP2014097934A (ja) * | 2012-11-13 | 2014-05-29 | Ajinomoto Co Inc | アミノ酸化合物の酢酸塩を含有する化粧料組成物 |
| US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
| US10073104B2 (en) | 2013-03-14 | 2018-09-11 | Siemens Healthcare Diagnostics Inc. | Control of pH in aqueous urea-containing solutions utilizing amino acid-containing compositions |
| US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
| US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
| US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
| US12312352B2 (en) | 2012-05-14 | 2025-05-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in SIRS and/or sepsis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5550925A (en) * | 1978-10-09 | 1980-04-14 | Sakura Kogyo Kk | Muffler silencer producing device |
| US4424232A (en) * | 1982-05-19 | 1984-01-03 | Parkinson Richard W | Treatment of herpes simplex |
| JPS5920217A (ja) * | 1982-07-27 | 1984-02-01 | Kawaken Fine Chem Co Ltd | 尿素を安定に含む水性ゼリ−状組成物 |
-
1984
- 1984-07-23 JP JP15258284A patent/JPS6130567A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5550925A (en) * | 1978-10-09 | 1980-04-14 | Sakura Kogyo Kk | Muffler silencer producing device |
| US4424232A (en) * | 1982-05-19 | 1984-01-03 | Parkinson Richard W | Treatment of herpes simplex |
| JPS5920217A (ja) * | 1982-07-27 | 1984-02-01 | Kawaken Fine Chem Co Ltd | 尿素を安定に含む水性ゼリ−状組成物 |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067701U (ja) * | 1992-07-02 | 1994-02-01 | 旭光学工業株式会社 | 内視鏡の送気装置 |
| WO1997005862A3 (en) * | 1995-08-03 | 1997-04-17 | Sigma Tau Ind Farmaceuti | Use of basic amino acids and derivatives for lowering ceramide levels |
| US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP2006524199A (ja) * | 2003-04-24 | 2006-10-26 | ロレアル | 美容的ピーリング方法 |
| US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US12171767B2 (en) | 2006-05-04 | 2024-12-24 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US12178819B2 (en) | 2006-05-04 | 2024-12-31 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
| US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
| US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US8440172B2 (en) | 2007-07-09 | 2013-05-14 | Symrise Ag | Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0 |
| US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
| US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
| US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| US12312352B2 (en) | 2012-05-14 | 2025-05-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in SIRS and/or sepsis |
| JP2014097934A (ja) * | 2012-11-13 | 2014-05-29 | Ajinomoto Co Inc | アミノ酸化合物の酢酸塩を含有する化粧料組成物 |
| US11921124B2 (en) | 2013-03-14 | 2024-03-05 | Siemens Healthcare Diagnostics Inc. | Control of pH in aqueous urea-containing solutions utilizing amino acid-containing compositions |
| US10073104B2 (en) | 2013-03-14 | 2018-09-11 | Siemens Healthcare Diagnostics Inc. | Control of pH in aqueous urea-containing solutions utilizing amino acid-containing compositions |
| US10921333B2 (en) | 2013-03-14 | 2021-02-16 | Siemens Healthcare Diagnostics Inc. | Control of pH in aqueous urea-containing solutions utilizing amino acid-containing compositions |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
| US12364700B2 (en) | 2016-06-10 | 2025-07-22 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0531540B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6130567A (ja) | 尿素の安定化法 | |
| JP2898213B2 (ja) | アスコルビン酸を安定な状態で含有するエマルションおよびこれを用いた美容処理方法 | |
| US4818521A (en) | Emulsion cosmetic stably containing vitamin C | |
| JPH0940545A (ja) | アスコルビン酸を含有する安定組成物 | |
| JPS60104005A (ja) | 美白化粧料 | |
| JPH0330566B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS6245527A (ja) | 白髪予防、治療剤 | |
| JPH02207018A (ja) | 皮膚外用剤 | |
| JPS6241645B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPH0745387B2 (ja) | 発毛、養毛促進剤 | |
| JP2000198719A (ja) | 発毛剤 | |
| JPS59134772A (ja) | 尿素の安定化法 | |
| JP4926354B2 (ja) | 皮膚外用剤 | |
| JP2589761B2 (ja) | 化粧品添加物 | |
| JPS60185757A (ja) | 尿素の安定化法 | |
| JPS6130509A (ja) | 皮膚外用剤 | |
| JP2003206224A (ja) | 外用組成物 | |
| JPH0531541B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP3441387B2 (ja) | 保湿剤及び皮膚化粧料並びに入浴剤 | |
| RU2036640C1 (ru) | Мазь для лечения заболеваний с нарушением керотинизации и целостности кожи | |
| CA1081124A (en) | Thiazole derivatives | |
| JPS6147457A (ja) | 尿素の安定化法 | |
| JPS6147456A (ja) | 尿素の安定化法 | |
| JPH08268861A (ja) | 皮膚外用剤 | |
| JPH02145503A (ja) | 皮膚外用剤 |